LC-MS/MS extends the range of drug analysis in pain patients.
The current study addresses the distribution of low concentrations of excreted drugs in the pain patient population in an effort to establish a more rational set of cutoffs for this cohort. To wit, 19 analytes in approximately 8000 urine specimens from pain patients were measured using liquid chromatography tandem mass spectroscopy (LC-MS/MS) methodology. The lower limits of quantitation for the LC-MS/MS were set as the nominal cutoffs for the determination of positive and negative results. The measured concentrations were compared with the Substance Abuse & Mental Health Services Administration (SAMHSA) nominal immunoassay cutoffs, and a subset of "missed samples" was identified for each of the 19 analytes. This "missed samples" subset contained all samples that measured above the LC MS/MS cutoff for a given analyte but below the SAMHSA immunoassay cutoff. The number of "missed samples" divided by the total number of samples measured positive by the LC-MS/MS method defines the percentage of this population that would have been found falsely negative if a prescreen by immunoassay using SAMHSA cutoffs had been conducted. For example, 69% of the specimens that were positive for hydromorphone by LC-MS/MS would have been falsely scored as negative by immunoassay.